O	O	O	0	11	Lymphocytes	Lymphocyte	B-NP	NNS	B-cell_type	5	SUB	B-cell_type
O	O	O	12	16	from	from	B-PP	IN	O	1	NMOD	O
O	O	O	17	20	CML	CML	B-NP	NN	O	4	NMOD	O
O	O	O	21	29	patients	patient	I-NP	NNS	O	2	PMOD	O
O	O	O	30	34	lack	lack	B-VP	VBP	O	0	ROOT	O
O	O	O	35	36	a	a	B-NP	DT	O	9	NMOD	O
O	O	O	37	39	47	47	I-NP	CD	B-protein	8	AMOD	B-protein
O	O	O	40	43	kDa	kDa	I-NP	NN	I-protein	9	NMOD	I-protein
O	O	O	44	50	factor	factor	I-NP	NN	I-protein	5	OBJ	I-protein
O	O	O	51	57	having	have	B-VP	VBG	O	9	NMOD	O
O	O	O	58	66	affinity	affinity	B-NP	NN	O	10	OBJ	O
O	O	O	67	70	for	for	B-PP	IN	O	11	NMOD	O
O	O	O	71	72	a	a	B-NP	DT	O	17	NMOD	O
T2	B-Entity	B-Entity	73	80	genomic	genomic	I-NP	JJ	B-DNA	17	NMOD	B-DNA
T2	I-Entity	I-Entity	81	87	sterol	sterol	I-NP	NN	I-DNA	17	NMOD	I-DNA
T2	I-Entity	I-Entity	88	98	regulatory	regulatory	I-NP	JJ	I-DNA	17	NMOD	I-DNA
T2	I-Entity	I-Entity	99	107	sequence	sequence	I-NP	NN	I-DNA	12	PMOD	I-DNA
O	O	O	107	108	.	.	O	.	O	5	P	O

O	O	O	110	118	Deranged	Deranged	B-NP	JJ	O	4	NMOD	O
O	O	O	119	127	cellular	cellular	I-NP	JJ	O	4	NMOD	O
O	O	O	128	139	cholesterol	cholesterol	I-NP	NN	O	4	NMOD	O
O	O	O	140	151	homeostasis	homeostasis	I-NP	NN	O	5	SUB	O
O	O	O	152	155	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	156	160	been	be	I-VP	VBN	O	5	VC	O
O	O	O	161	167	widely	widely	I-VP	RB	O	6	VMOD	O
O	O	O	168	178	recognized	recognize	I-VP	VBN	O	6	VC	O
O	O	O	179	181	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	182	185	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	186	196	initiation	initiation	I-NP	NN	O	9	PMOD	O
O	O	O	197	199	as	as	B-CONJP	RB	O	9	PMOD	O
O	O	O	200	204	well	well	I-CONJP	RB	O	12	DEP	O
O	O	O	205	207	as	as	I-CONJP	IN	O	12	DEP	O
O	O	O	208	219	progression	progression	B-NP	NN	O	9	PMOD	O
O	O	O	220	222	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	223	230	various	various	B-NP	JJ	O	18	NMOD	O
O	O	O	231	236	types	type	I-NP	NNS	O	16	PMOD	O
O	O	O	237	239	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	240	247	cancers	cancer	B-NP	NNS	O	19	PMOD	O
O	O	O	248	257	including	include	B-PP	VBG	O	18	NMOD	O
O	O	O	258	265	chronic	chronic	B-NP	JJ	O	24	NMOD	O
O	O	O	266	273	myeloid	myeloid	I-NP	JJ	O	24	NMOD	O
O	O	O	274	283	leukaemia	leukaemia	I-NP	NN	O	21	PMOD	O
O	O	O	284	285	(	(	O	(	O	27	DEP	O
O	O	O	285	288	CML	CML	B-NP	NN	O	27	DEP	O
O	O	O	288	289	)	)	O	)	O	24	NMOD	O
O	O	O	289	290	.	.	O	.	O	5	P	O

O	O	O	291	296	Since	Since	B-SBAR	IN	O	27	VMOD	O
O	O	O	297	300	the	the	B-NP	DT	O	7	NMOD	O
T3	B-Entity	B-Entity	301	306	human	human	I-NP	JJ	B-DNA	7	NMOD	B-DNA
T3	I-Entity	I-Entity	307	314	genomic	genomic	I-NP	JJ	I-DNA	7	NMOD	I-DNA
T3	I-Entity	I-Entity	315	321	sterol	sterol	I-NP	NN	I-DNA	7	NMOD	I-DNA
T3	I-Entity	I-Entity	322	332	regulatory	regulatory	I-NP	JJ	I-DNA	7	NMOD	I-DNA
T3	I-Entity	I-Entity	333	340	element	element	I-NP	NN	I-DNA	11	SUB	I-DNA
O	O	O	341	342	(	(	O	(	O	10	DEP	O
T4	B-Entity	B-Entity	342	345	SRE	SRE	B-NP	NN	B-DNA	10	DEP	B-DNA
O	O	O	345	346	)	)	O	)	O	7	NMOD	O
O	O	O	347	350	has	have	B-VP	VBZ	O	1	SBAR	O
O	O	O	351	355	been	be	I-VP	VBN	O	11	VC	O
O	O	O	356	361	shown	show	I-VP	VBN	O	12	VC	O
O	O	O	362	364	to	to	I-VP	TO	O	15	VMOD	O
O	O	O	365	373	regulate	regulate	I-VP	VB	O	13	VMOD	O
T5	B-Entity	B-Entity	374	381	various	various	B-NP	JJ	O	18	NMOD	O
T5	I-Entity	I-Entity	382	385	key	key	I-NP	JJ	O	18	NMOD	O
T5	I-Entity	I-Entity	386	391	genes	gene	I-NP	NNS	O	15	OBJ	O
O	O	O	392	400	involved	involve	B-VP	VBN	O	18	NMOD	O
O	O	O	401	403	in	in	B-PP	IN	O	19	VMOD	O
O	O	O	404	408	this	this	B-NP	DT	O	22	NMOD	O
O	O	O	409	419	phenomenon	phenomenon	I-NP	NN	O	20	PMOD	O
O	O	O	419	420	,	,	O	,	O	27	P	O
O	O	O	421	424	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	425	432	present	present	I-NP	JJ	O	26	NMOD	O
O	O	O	433	438	study	study	I-NP	NN	O	27	SUB	O
O	O	O	439	447	revealed	reveal	B-VP	VBD	O	0	ROOT	O
O	O	O	448	451	the	the	B-NP	DT	O	29	NMOD	O
O	O	O	452	461	existence	existence	I-NP	NN	O	53	NMOD	O
O	O	O	462	464	of	of	B-PP	IN	O	29	NMOD	O
O	O	O	465	466	a	a	B-NP	DT	O	36	NMOD	O
O	O	O	467	473	unique	unique	I-NP	JJ	B-protein	36	NMOD	B-protein
O	O	O	474	476	47	47	I-NP	CD	I-protein	34	AMOD	I-protein
O	O	O	477	480	kDa	kDa	I-NP	NN	I-protein	36	NMOD	I-protein
O	O	O	481	488	protein	protein	I-NP	NN	I-protein	36	NMOD	I-protein
O	O	O	489	495	factor	factor	I-NP	NN	I-protein	30	PMOD	I-protein
O	O	O	496	502	having	have	B-VP	VBG	O	36	NMOD	O
O	O	O	503	511	affinity	affinity	B-NP	NN	O	37	OBJ	O
O	O	O	512	515	for	for	B-PP	IN	O	38	NMOD	O
O	O	O	516	520	this	this	B-NP	DT	O	42	NMOD	O
T6	B-Entity	B-Entity	521	524	SRE	SRE	I-NP	NN	B-DNA	42	NMOD	B-DNA
T6	I-Entity	I-Entity	525	533	sequence	sequence	I-NP	NN	I-DNA	39	PMOD	I-DNA
O	O	O	534	536	in	in	B-PP	IN	O	29	NMOD	O
O	O	O	537	548	lymphocytes	lymphocyte	B-NP	NNS	B-cell_type	43	PMOD	B-cell_type
O	O	O	549	553	from	from	B-PP	IN	O	44	NMOD	O
O	O	O	554	560	normal	normal	B-NP	JJ	O	47	NMOD	O
O	O	O	561	569	subjects	subject	I-NP	NNS	O	45	PMOD	O
O	O	O	569	570	,	,	O	,	O	53	P	O
O	O	O	571	573	as	as	B-CONJP	RB	O	53	NMOD	O
O	O	O	574	578	well	well	I-CONJP	RB	O	49	DEP	O
O	O	O	579	581	as	as	I-CONJP	IN	O	49	DEP	O
O	O	O	582	585	its	its	B-NP	PRP$	O	53	NMOD	O
O	O	O	586	593	absence	absence	I-NP	NN	O	27	OBJ	O
O	O	O	594	596	in	in	B-PP	IN	O	53	NMOD	O
O	O	O	597	608	lymphocytes	lymphocyte	B-NP	NNS	B-cell_type	54	PMOD	B-cell_type
O	O	O	609	613	from	from	B-PP	IN	O	55	NMOD	O
O	O	O	614	623	untreated	untreated	B-NP	JJ	O	59	NMOD	O
O	O	O	624	627	CML	CML	I-NP	NN	O	59	NMOD	O
O	O	O	628	636	patients	patient	I-NP	NNS	O	56	PMOD	O
O	O	O	636	637	.	.	O	.	O	27	P	O

O	O	O	638	645	However	However	B-ADVP	RB	O	5	VMOD	O
O	O	O	645	646	,	,	O	,	O	5	P	O
O	O	O	647	651	this	this	B-NP	DT	O	4	NMOD	O
O	O	O	652	658	factor	factor	I-NP	NN	O	5	SUB	O
O	O	O	659	667	appeared	appear	B-VP	VBD	O	0	ROOT	O
O	O	O	668	672	when	when	B-ADVP	WRB	O	5	VMOD	O
O	O	O	673	678	these	these	B-NP	DT	O	9	NMOD	O
O	O	O	679	682	CML	CML	I-NP	NN	O	9	NMOD	O
O	O	O	683	691	patients	patient	I-NP	NNS	O	10	SUB	O
O	O	O	692	700	achieved	achieve	B-VP	VBD	O	6	SBAR	O
O	O	O	701	709	complete	complete	B-NP	JJ	O	13	NMOD	O
O	O	O	710	724	haematological	haematological	I-NP	JJ	O	13	NMOD	O
O	O	O	725	734	remission	remission	I-NP	NN	O	10	OBJ	O
O	O	O	735	736	(	(	O	(	O	16	DEP	O
O	O	O	736	739	CHR	CHR	B-NP	NN	O	16	DEP	O
O	O	O	739	740	)	)	O	)	O	13	NMOD	O
O	O	O	741	748	through	through	B-PP	IN	O	10	VMOD	O
O	O	O	749	754	alpha	alpha	B-NP	SYM	B-protein	21	NMOD	B-protein
O	O	O	754	755	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
O	O	O	755	765	interferon	interferon	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	O	766	773	therapy	therapy	I-NP	NN	O	17	PMOD	O
O	O	O	773	774	.	.	O	.	O	5	P	O

O	O	O	775	786	Furthermore	Furthermore	B-ADVP	RB	O	6	VMOD	O
O	O	O	786	787	,	,	O	,	O	6	P	O
O	O	O	788	790	an	an	B-NP	DT	O	5	NMOD	O
O	O	O	791	798	inverse	inverse	I-NP	JJ	O	5	NMOD	O
O	O	O	799	811	relationship	relationship	I-NP	NN	O	6	SUB	O
O	O	O	812	815	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	816	820	also	also	I-VP	RB	O	6	VMOD	O
O	O	O	821	829	observed	observe	I-VP	VBN	O	6	VC	O
O	O	O	830	837	between	between	B-PP	IN	O	8	VMOD	O
O	O	O	838	841	the	the	B-NP	DT	O	14	NMOD	O
T1	B-Protein	B-Protein	842	845	LDL	LDL	I-NP	NN	B-DNA	14	NMOD	B-DNA
T1	I-Protein	I-Protein	846	854	receptor	receptor	I-NP	NN	I-DNA	14	NMOD	I-DNA
O	O	O	855	859	gene	gene	I-NP	NN	I-DNA	14	NMOD	I-DNA
O	O	O	860	870	expression	expression	I-NP	NN	O	22	NMOD	O
O	O	O	871	873	at	at	B-PP	IN	O	14	NMOD	O
O	O	O	874	877	the	the	B-NP	DT	O	18	NMOD	O
O	O	O	878	893	transcriptional	transcriptional	I-NP	JJ	O	18	NMOD	O
O	O	O	894	899	level	level	I-NP	NN	O	15	PMOD	O
O	O	O	900	903	and	and	O	CC	O	22	NMOD	O
O	O	O	904	907	the	the	B-NP	DT	O	22	NMOD	O
O	O	O	908	915	binding	binding	I-NP	NN	O	22	NMOD	O
O	O	O	916	924	affinity	affinity	I-NP	NN	O	9	PMOD	O
O	O	O	925	927	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	928	932	this	this	B-NP	DT	O	28	NMOD	O
O	O	O	933	935	47	47	I-NP	CD	B-protein	26	AMOD	B-protein
O	O	O	936	939	kDa	kDa	I-NP	NN	I-protein	28	NMOD	I-protein
O	O	O	940	947	protein	protein	I-NP	NN	I-protein	28	NMOD	I-protein
O	O	O	948	954	factor	factor	I-NP	NN	I-protein	23	PMOD	I-protein
O	O	O	955	957	to	to	B-PP	TO	O	22	NMOD	O
O	O	O	958	961	the	the	B-NP	DT	O	32	NMOD	O
T7	B-Entity	B-Entity	962	965	SRE	SRE	I-NP	NN	B-DNA	32	NMOD	B-DNA
T7	I-Entity	I-Entity	966	974	sequence	sequence	I-NP	NN	I-DNA	29	PMOD	I-DNA
O	O	O	974	975	.	.	O	.	O	6	P	O

O	O	O	976	981	Based	Base	B-VP	VBN	O	6	VMOD	O
O	O	O	982	986	upon	upon	B-PP	IN	O	1	PMOD	O
O	O	O	987	992	these	these	B-NP	DT	O	4	NMOD	O
O	O	O	993	1000	results	result	I-NP	NNS	O	2	PMOD	O
O	O	O	1001	1003	we	we	B-NP	PRP	O	6	SUB	O
O	O	O	1004	1011	propose	propose	B-VP	VBP	O	0	ROOT	O
O	O	O	1012	1016	that	that	B-SBAR	IN	O	6	VMOD	O
O	O	O	1017	1021	this	this	B-NP	DT	O	9	NMOD	O
O	O	O	1022	1028	factor	factor	I-NP	NN	O	10	SUB	O
O	O	O	1029	1032	may	may	B-VP	MD	O	7	SBAR	O
O	O	O	1033	1037	have	have	I-VP	VB	O	10	VC	O
O	O	O	1038	1039	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	1040	1044	role	role	I-NP	NN	O	11	OBJ	O
O	O	O	1045	1047	in	in	B-PP	IN	O	11	VMOD	O
O	O	O	1048	1063	pathophysiology	pathophysiology	B-NP	NN	O	14	PMOD	O
O	O	O	1064	1066	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	1067	1074	chronic	chronic	B-NP	JJ	O	19	NMOD	O
O	O	O	1075	1082	myeloid	myeloid	I-NP	JJ	O	19	NMOD	O
O	O	O	1083	1092	leukaemia	leukaemia	I-NP	NN	O	16	PMOD	O
O	O	O	1092	1093	.	.	O	.	O	6	P	O
